Literature DB >> 13130486

A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice.

Kim W McIntyre1, David J Shuster, Kathleen M Gillooly, Donna M Dambach, Mark A Pattoli, Pin Lu, Xia-Di Zhou, Yuping Qiu, F Christopher Zusi, James R Burke.   

Abstract

OBJECTIVE: The transcription of several cytokines, cell adhesion molecules, and enzymes involved in the inflammatory and destructive mechanisms of rheumatoid arthritis is dependent on nuclear factor kappa B (NF-kappa B). Because I kappa B kinase (IKK) is critical in transducing the signal-inducible activation of NF-kappa B, we examined whether the highly selective and orally bioavailable IKK inhibitor BMS-345541 is efficacious against collagen-induced arthritis (CIA) in mice.
METHODS: Arthritis in DBA/1LacJ male mice was induced by subcutaneous immunization with bovine type II collagen on day 0 and day 21. BMS-345541 was administered perorally daily, either prophylactically (before disease onset) or therapeutically (after disease onset). Clinical assessment of the incidence and severity of disease was conducted throughout the study, and histologic evaluation was performed at the time of study termination (day 42).
RESULTS: When administered prophylactically, BMS-345541 (in a dose range of 10-100 mg/kg) was effective, in a dose-dependent manner, in reducing the incidence of disease and inhibiting clinical signs of disease. Histologic evaluation of the joints showed that both inflammation and joint destruction were blocked by the IKK inhibitor. Message levels of interleukin-1 beta in the joints were also dose-dependently inhibited in the mice that received BMS-345541. Dose-dependent efficacy in terms of both disease severity and histologic end points was observed with the therapeutic dosing regimen of BMS-345541, with use of the 100-mg/kg dose resulting in resolution of disease.
CONCLUSION: IKK plays a key role in CIA in mice, and inhibitors of this enzyme represent a promising target for the development of novel agents to treat rheumatoid arthritis and other inflammatory diseases. BMS-345541 represents the first example of an inhibitor of IKK that has antiinflammatory activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13130486     DOI: 10.1002/art.11131

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  72 in total

Review 1.  Role of NF-κB in the skeleton.

Authors:  Deborah Veis Novack
Journal:  Cell Res       Date:  2010-11-16       Impact factor: 25.617

2.  Damped oscillations in a multiple delayed feedback NF-κB signaling module.

Authors:  Wen-Ting Yu; Jun Tang; Jun Ma; Jin-Ming Luo; Xian-Qing Yang
Journal:  Eur Biophys J       Date:  2015-08-20       Impact factor: 1.733

3.  Pyrroloquinoline Quinone Decelerates Rheumatoid Arthritis Progression by Inhibiting Inflammatory Responses and Joint Destruction via Modulating NF-κB and MAPK Pathways.

Authors:  Zhongbing Liu; Chi Sun; Ran Tao; Xinbao Xu; Libin Xu; Hongbing Cheng; Youhua Wang; Dongmei Zhang
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

4.  Quercetin inhibits IL-1β-induced proliferation and production of MMPs, COX-2, and PGE2 by rheumatoid synovial fibroblast.

Authors:  Myung-Soon Sung; Eun-Gyeong Lee; Hyun-Soon Jeon; Han-Jung Chae; Seoung Ju Park; Yong Chul Lee; Wan-Hee Yoo
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

Review 5.  Inflammation-activated protein kinases as targets for drug development.

Authors:  Michael Karin
Journal:  Proc Am Thorac Soc       Date:  2005

Review 6.  Novel host response therapeutic approaches to treat periodontal diseases.

Authors:  Keith L Kirkwood; Joni A Cirelli; Jill E Rogers; William V Giannobile
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

7.  A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity.

Authors:  Karl Ziegelbauer; Florian Gantner; Nicholas W Lukacs; Aaron Berlin; Kinji Fuchikami; Toshiro Niki; Katsuya Sakai; Hisayo Inbe; Keisuke Takeshita; Mina Ishimori; Hiroshi Komura; Toshiki Murata; Timothy Lowinger; Kevin B Bacon
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

8.  BMS-345541 sensitizes MCF-7 breast cancer cells to ionizing radiation by selective inhibition of homologous recombinational repair of DNA double-strand breaks.

Authors:  Lixian Wu; Lijian Shao; Manna Li; Junying Zheng; Junru Wang; Wei Feng; Jianhui Chang; Yan Wang; Martin Hauer-Jensen; Daohong Zhou
Journal:  Radiat Res       Date:  2012-12-21       Impact factor: 2.841

9.  Opposing functions of IKKbeta during acute and chronic intestinal inflammation.

Authors:  Lars Eckmann; Tim Nebelsiek; Alexander A Fingerle; Sara M Dann; Jörg Mages; Roland Lang; Sylvie Robine; Martin F Kagnoff; Roland M Schmid; Michael Karin; Melek C Arkan; Florian R Greten
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

Review 10.  Intracellular signal pathways: potential for therapies.

Authors:  Melissa Mavers; Eric M Ruderman; Harris Perlman
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.